Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Kao WY, Chang IW, Chen CL, Su CW, Fang SU, Tang JH, Chang CC, Chang YJ, Wang W.

Obes Surg. 2020 Jan 18. doi: 10.1007/s11695-019-04192-w. [Epub ahead of print]

PMID:
31953745
2.

Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway.

Chyau CC, Wang HF, Zhang WJ, Chen CC, Huang SH, Chang CC, Peng RY.

Int J Mol Sci. 2020 Jan 6;21(1). pii: E360. doi: 10.3390/ijms21010360.

3.

How does lesion size affect the pooled effect of traction-assisted endoscopic submucosal dissection on procedure time? A meta-regression.

Cheng SW, Chang CC, Su YF, Kang YN.

World J Surg Oncol. 2019 Sep 10;17(1):157. doi: 10.1186/s12957-019-1699-0.

4.

Infection rate among nutritional therapies for acute pancreatitis: A systematic review with network meta-analysis of randomized controlled trials.

Hsieh PH, Su HY, Lin CY, Kang YN, Chang CC.

PLoS One. 2019 Jul 10;14(7):e0219151. doi: 10.1371/journal.pone.0219151. eCollection 2019.

5.

The Prognosis of Single Large Hepatocellular Carcinoma Was Distinct from Barcelona Clinic Liver Cancer Stage A or B: The Role of Albumin-Bilirubin Grade.

Fang KC, Kao WY, Su CW, Chen PC, Lee PC, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC.

Liver Cancer. 2018 Oct;7(4):335-358. doi: 10.1159/000487407. Epub 2018 Mar 14.

6.

Tumor-Targeted Immunotherapy by Using Primary Adipose-Derived Stem Cells and an Antigen-Specific Protein Vaccine.

Lu JH, Peng BY, Chang CC, Dubey NK, Lo WC, Cheng HC, Wang JR, Wei HJ, Deng WP.

Cancers (Basel). 2018 Nov 15;10(11). pii: E446. doi: 10.3390/cancers10110446.

7.

A rare cause of hematochezia after colonoscopy.

Kao WY, Tiong C, Chang CC.

Dig Liver Dis. 2019 Mar;51(3):452. doi: 10.1016/j.dld.2018.09.006. Epub 2018 Sep 20. No abstract available.

PMID:
30309750
8.

Toward population specific and personalized treatment of Helicobacter pylori infection.

Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

J Biomed Sci. 2018 Oct 2;25(1):70. doi: 10.1186/s12929-018-0471-z. Review.

9.

Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C.

Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC.

Hepatology. 2019 Mar;69(3):1151-1164. doi: 10.1002/hep.30247. Epub 2019 Feb 7.

PMID:
30175498
10.

The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus.

Cheng HC, Liou JM, Luo JC, Chiu CT, Wu MS, Lee YC, Wu CY, Wu DC, Hsu PI, Chang CC, Chang WL, Lin JT, Sheu BS.

Helicobacter. 2018 Oct;23(5):e12533. doi: 10.1111/hel.12533. Epub 2018 Aug 29.

PMID:
30159952
11.

Red Blood Cell Aggregation-Associated Dietary Pattern Predicts Hyperlipidemia and Metabolic Syndrome.

Lin P, Chang CC, Yuan KC, Yeh HJ, Fang SU, Cheng T, Teng KT, Chao KC, Tang JH, Kao WY, Lin PY, Liu JS, Chang JS.

Nutrients. 2018 Aug 20;10(8). pii: E1127. doi: 10.3390/nu10081127.

12.

STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening.

Cheng CC, Liao PN, Ho AS, Lim KH, Chang J, Su YW, Chen CG, Chiang YW, Yang BL, Lin HC, Chang YC, Chang CC, Chang YF.

J Biomed Sci. 2018 Aug 2;25(1):60. doi: 10.1186/s12929-018-0456-y.

13.

Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.

Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Gastroenterology. 2018 Oct;155(4):1109-1119. doi: 10.1053/j.gastro.2018.06.047. Epub 2018 Jun 30.

PMID:
29964036
14.

14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial.

Liou JM, Chen CC, Fang YJ, Chen PY, Chang CY, Chou CK, Chen MJ, Tseng CH, Lee JY, Yang TH, Chiu MC, Yu JJ, Kuo CC, Luo JC, Hsu WF, Hu WH, Tsai MH, Lin JT, Shun CT, Twu G, Lee YC, Bair MJ, Wu MS; Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium.

J Antimicrob Chemother. 2018 Sep 1;73(9):2510-2518. doi: 10.1093/jac/dky183.

PMID:
29846605
15.

An Easily Overlooked Cause of Mucus and Bloody Material Passage During Defecation in a 47-Year-Old Man.

Teng KT, Lee YJ, Chang CC.

Gastroenterology. 2018 Jun;154(8):e3-e4. doi: 10.1053/j.gastro.2017.06.058. Epub 2018 May 5. No abstract available.

PMID:
29738751
16.

Correction: Aminoazo dye-protein-adduct enhances inhibitory effect on digestibility and damages to Gastro-Duodenal-Hepatic axis.

Lin LY, Peng CC, Chen Y, Huang BC, Chang CC, Peng RY.

PLoS One. 2018 Apr 12;13(4):e0196026. doi: 10.1371/journal.pone.0196026. eCollection 2018.

17.

Taiwanofungus camphoratus Combined With Amphotericin B for Metastatic Cancer Patients Unresponsive to or Unwilling to Undergo Chemotherapy: A Pilot Study.

Tai CJ, Shi YC, Tai CJ, Kuo LJ, Chen RJ, Chang YJ, Tzao C, Wu CH, Chang CC, Chiou HY, Su CH.

Altern Ther Health Med. 2018 Feb 24. pii: AT5734. [Epub ahead of print]

PMID:
29477137
18.

Idiopathic mesenteric phlebosclerosis associated with long-term use of Chinese herbal medicine.

Yeh HJ, Lin PY, Kao WY, Kun CH, Chang CC.

Turk J Gastroenterol. 2018 Jan;29(1):140-142. doi: 10.5152/tjg.2018.17072. No abstract available.

19.

SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft.

Shih BB, Chang YF, Cheng CC, Yang HJ, Chang KW, Ho AS, Lin HC, Yeh C, Chang CC.

J Chin Med Assoc. 2017 Dec;80(12):766-773. doi: 10.1016/j.jcma.2017.02.010. Epub 2017 Sep 29.

20.

YM155 as an inhibitor of cancer stemness simultaneously inhibits autophosphorylation of epidermal growth factor receptor and G9a-mediated stemness in lung cancer cells.

Cheng CC, Chang J, Huang SC, Lin HC, Ho AS, Lim KH, Chang CC, Huang L, Chang YC, Chang YF, Wu CW.

PLoS One. 2017 Aug 7;12(8):e0182149. doi: 10.1371/journal.pone.0182149. eCollection 2017.

Supplemental Content

Loading ...
Support Center